Non-alcoholic Fatty Liver Disease
563
79
100
289
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
62 trials with published results (11%)
Research Maturity
289 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.4%
25 terminated out of 563 trials
92.0%
+5.5% vs benchmark
9%
51 trials in Phase 3/4
21%
62 of 289 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 289 completed trials
Clinical Trials (563)
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
Dietary Allowance of Methyl Donor Nutrients to Minimize Risks of Non-alcoholic Fatty Liver Progression
The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
FibroScan-Reproducibility and Repeatability Study
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
Effect of Insulin Lowering on Lipogenesis
Human Models of Selective Insulin Resistance: Alpelisib, Part I
FCI Effectiveness in NAFLD Stratification
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
Vitamin E Dosing Study
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases
Phase 2b Study of GSK4532990 in Adults With NASH
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules
iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss